去氧孕烯
参考

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32  . Clin Obstet Gynecol. 1995, 38 (4): 821–8. PMID 8616978.
1 2 3 4 5 6 7 8 9 10  . Am. J. Obstet. Gynecol. 1993, 168 (3 Pt 2): 1021–8. PMID 8447355.
↑  Fotherby K. . Contraception. August 1996, 54 (2): 59–69. PMID 8842581. doi:10.1016/0010-7824(96)00136-9.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  Benno Clemens Runnebaum; Thomas Rabe; Ludwig Kiesel. . Springer Science & Business Media. 6 December 2012: 156–163. ISBN 978-3-642-73790-9.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46  . Drugs. 1996, 51 (2): 188–215. PMID 8808163.
1 2  . Mosby. 2001: 687. ISBN 978-0-323-00629-3. The elimination half-life for 3-keto-desogestrel is approximately 38 ± 20 hours at steady state.
↑  . drugs.dxy.cn.   [2019-02-08]. （原始内容存档于2018-06-20）.
↑   (PDF). Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology. 2011, 8 (Special Issue 1): 157–176  [2019-02-08]. （原始内容存档 (PDF)于2016-10-11）. Desogestrel was synthesized in 1972 at Organon [...]
↑  Jeremy A. Holtsclaw. . University of Michigan. 2007: 25. In 1981, desogestrel was marketed as a new low dose oral contraceptive under the trade names Marvelon® and Desogen®.32
1 2 3 4  . Ann Pharmacother. 1995, 29 (7-8): 736–42. PMID 8520092. doi:10.1177/106002809502907-817.
↑  Susan G. Kornstein; Anita H. Clayton. . Guilford Press. 15 December 2004: 114–. ISBN 978-1-59385-144-6.
↑  . Am. J. Obstet. Gynecol. 1994, 170 (5 Pt 2): 1550–5. PMID 8178905.
1 2  Howard J.A. Carp. . Springer. 9 April 2015: 112,136. ISBN 978-3-319-14385-9.
1 2 3  . Cochrane Database Syst Rev. 2013, (11): CD007541. PMID 24226383. doi:10.1002/14651858.CD007541.pub3.
1 2 3  . Contraception. 2004, 69 (2): 89–97. PMID 14759612. doi:10.1016/j.contraception.2003.09.002.
1 2 3 4 5  
. Drugs.com.   [2019-02-08]. （原始内容存档于2017-08-03） （英语）.
↑   https://www.drugs.com/availability/generic-desogen.html （页面存档备份，存于）
1 2  Michael Freissmuth; Stefan Böhm. . Springer Science & Business Media. 9 March 2012: 572–. ISBN 978-3-642-12353-5.
1 2 3  
 (PDF). www.drugs.com.   [2019-02-08]. （原始内容存档 (PDF)于2018-01-07）.
1 2   https://www.drugs.com/breastfeeding/desogestrel.html （页面存档备份，存于）
1 2 3 4 5 6 7 8 9 10 11 12 13  
. www.medicines.org.uk.   [2019-02-08]. （原始内容存档于2018-01-07）.
↑
↑  . Drugs.com.   [2019-02-08]. （原始内容存档于2016-03-01） （英语）.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16   (PDF). Climacteric. 2005,. 8 Suppl 1: 3–63  [2019-02-08]. PMID 16112947. doi:10.1080/13697130500148875. （原始内容存档 (PDF)于2016-08-22）.
1 2  Thomas L. Lemke; David A. Williams. . Lippincott Williams & Wilkins. 2008: 1316–. ISBN 978-0-7817-6879-5.
1 2 3 4  Wu, F. C.; Balasubramanian, R.; Mulders, T. M.; Coelingh-Bennink, H. J. . The Journal of Clinical Endocrinology and Metabolism. 1999-01, 84 (1): 112–122. ISSN 0021-972X. PMID 9920070. doi:10.1210/jcem.84.1.5412 .
1 2 3  . Am. J. Obstet. Gynecol. 1993, 168 (3 Pt 2): 1010–6. PMID 8447353.
↑  . Am. J. Obstet. Gynecol. 1962, 84 (7): 962–8. PMID 14450719. doi:10.1016/0002-9378(62)90075-3.
↑  . Am. J. Obstet. Gynecol. 1965, 93 (7): 1002–4. PMID 5843402. doi:10.1016/0002-9378(65)90162-6.
↑  Curwen, S. . BMJ. 1962, 1 (5289): 1415–1415. ISSN 0959-8138. doi:10.1136/bmj.1.5289.1415-a.
↑  . J Pediatr Adolesc Gynecol. 2012, 25 (2): 105–8. PMID 22154396. doi:10.1016/j.jpag.2011.09.013.
1 2 3  Kuhl, H. . Therapeutische Umschau. Revue Therapeutique. 2001-09, 58 (9): 527–533. ISSN 0040-5930. PMID 11594150. doi:10.1024/0040-5930.58.9.527.
1 2 3  J. Elks. . Springer. 14 November 2014: 364–. ISBN 978-1-4757-2085-3.
1 2 3 4  . Taylor & Francis. 2000: 305–. ISBN 978-3-88763-075-1.
↑  KD Tripathi. . JP Medical Ltd. 30 September 2013: 316–. ISBN 978-93-5025-937-5.
↑  Gretchen M. Lentz. . Elsevier Health Sciences. 2012: 223–. ISBN 0-323-06986-X.
↑  Sven O. Skouby. . CRC Press. 15 July 1997: 11–. ISBN 978-1-85070-786-8.
↑  Van Den Broek, A. J.; Van Bokhoven, C.; Hobbelen, P. M. J.; Leemhuis, J. . Recueil des Travaux Chimiques des Pays-Bas. 1975, 94 (2): 35. doi:10.1002/recl.19750940203.
1 2  . United States Food and Drug Administration.   [6 January 2018]. （原始内容存档于2016-11-16）.
1 2   Public Citizen's Health Research Group： 请求美国食品和药物管理局禁止因静脉血栓形成风险增加而含有去氧孕烯的第三代口服避孕药 （页面存档备份，存于） HRG出版物＃ 1799,2007 （页面存档备份，存于）
1 2  公众认为两次关于第三代口服避孕药和YASMIN （页面存档备份，存于）最差药丸，最好的药丸，2009年12月
↑  Lidegaard, Øjvind; Nielsen, Lars Hougaard; Skovlund, Charlotte Wessel; Skjeldestad, Finn Egil; Løkkegaard, Ellen. . BMJ. 2011-10-25, 343: d6423  [2019-02-08]. ISSN 0959-8138. PMC 3202015 . PMID 22027398. doi:10.1136/bmj.d6423. （原始内容存档于2017-07-31） （英语）. Progestogen only products conferred no increased risk of venous thromboembolism, whether taken as low dose norethisterone pills, as desogestrel only pills, or in the form of hormone releasing intrauterine devices.
1 2  . Contraception. 2010, 82 (5): 457–70. PMID 20933120. doi:10.1016/j.contraception.2010.03.020.
↑  . Cochrane Database Syst Rev. 2012, (3): CD004316. PMID 22419294. doi:10.1002/14651858.CD004316.pub4.
依托孕烯（3-酮去氧孕烯），去氧孕烯的活性形式。